Cannula for minimizing dilution of dosing during nitric oxide delivery

US9795756B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9795756-B2
Application numberUS-201314096548-A
CountryUS
Kind codeB2
Filing dateDec 4, 2013
Priority dateDec 4, 2012
Publication dateOct 24, 2017
Grant dateOct 24, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a flapper or umbrella valve dedicated to nitric oxide delivery. The nasal cannulas may also use materials that limit oxygen diffusion through the cannula walls. The nosepiece for these cannulas may be manufactured by a molding technique.

First claim

Opening claim text (preview).

What is claimed is: 1. A nasal cannula for therapeutic gas delivered to a patient, comprising: a nitric oxide source; an oxygen source; a first lumen, a second lumen, and a third lumen: the first lumen being a first therapeutic gas lumen for delivering a first therapeutic gas comprising nitric oxide from the nitric oxide source to the patient, the second lumen being a triggering lumen, and the third lumen being a second therapeutic gas lumen for delivering a second therapeutic gas comprising oxygen from the oxygen source to the patient; and a cannula nosepiece allowing separate flow paths to the patient for each of (i) the first therapeutic gas lumen, (ii) the triggering lumen, and (iii) the second therapeutic gas lumen; and wherein the cannula nosepiece comprises a nitric oxide flow path having an inner diameter that is smaller than an inner diameter of the first therapeutic gas lumen. 2. The nasal cannula of claim 1 , wherein the nasal cannula one or more of (i) reduces dilution of one or more of the first and second therapeutic gases delivered to the patient and (ii) is configured to be placed in fluid communication with at least one system to deliver one or more of the first and second therapeutic gases to the patient. 3. The nasal cannula of claim 1 , wherein the nasal cannula delivers one or more of the first and second therapeutic gases to the patient for treatment of one or more of chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH). 4. The nasal cannula of claim 1 , wherein the first therapeutic gas is nitric oxide and the second therapeutic gas is oxygen, and wherein the first therapeutic gas lumen for delivering nitric oxide is smaller than both of the second therapeutic gas lumen for delivering oxygen and the triggering lumen. 5. The nasal cannula of claim 1 , wherein one or more of (i) the first therapeutic gas is nitric oxide and the first therapeutic gas lumen for delivering nitric oxide has an inner diameter of about 0.01 inches to about 0.08 inches and (ii) the triggering lumen has an inner diameter of about 0.05 inches to about 0.12 inches. 6. The nasal cannula of claim 1 , wherein the nasal cannula is further comprising one or more of (i) a wall material having a low oxygen diffusion coefficient and (ii) at least one valve in fluid communication with the first therapeutic gas lumen. 7. The nasal cannula of claim 1 , wherein the cannula is further comprising a fourth lumen: the fourth lumen being another first therapeutic gas lumen for delivering the first therapeutic gas to the patient; and wherein the first lumen is adapted to deliver the first therapeutic gas to one nostril of the patient and the fourth lumen is adapted to deliver the first therapeutic gas to another nostril of the patient. 8. A nasal cannula for therapeutic gas delivered to a patient, comprising: a nitric oxide source; an oxygen source; a first lumen and a second lumen: the first lumen being a combined first therapeutic gas and triggering lumen for both delivering a first therapeutic gas comprising nitric oxide from the nitric oxide source to the patient and triggering, and the second lumen being a second therapeutic gas lumen for delivering a second therapeutic gas comprising oxygen from the oxygen source to the patient, the combined first therapeutic gas and triggering lumen having an inner diameter that is smaller than an inner diameter of the second therapeutic gas lumen; and a cannula nosepiece allowing separate flow paths to the patient for each of (i) the combined first therapeutic gas and triggering lumen and (ii) the second therapeutic gas lumen; and wherein the cannula nosepiece comprises a nitric oxide flow path having an inner diameter that is smaller than an inner diameter of the combined first therapeutic gas and triggering lumen. 9. The nasal cannula of claim 8 , wherein the nasal cannula one or more of (i) reduces dilution of one or more of the first and second therapeutic gases delivered to the patient and (ii) is configured to be placed in fluid communication with at least one system to deliver one or more of the first and second therapeutic gases to the patient. 10. The nasal cannula of claim 8 , wherein the nasal cannula delivers one or more of the first and second therapeutic gases to the patient for treatment of one or more of chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH). 11. The nasal cannula of claim 8 , wherein one or more of (i) the first therapeutic gas is nitric oxide and the combined first therapeutic gas and triggering lumen has an inner diameter of about 0.01 inches to about 0.08 inches and (ii) the first therapeutic gas is nitric oxide and the cannula nosepiece comprises a combined nitric oxide and triggering flow path having an inner diameter that is smaller than an inner diameter of the combined first therapeutic gas and triggering lumen. 12. The nasal cannula of claim 8 , wherein the nasal cannula is further comprising one or more of (i) a wall material having a low oxygen diffusion coefficient and (ii) at least one valve in fluid communication with the first therapeutic gas lumen. 13. A method of administering nitric oxide for treating pulmonary hypertension, the method comprising: administering a pulse of a gas comprising nitric oxide to a patient, wherein the pulse is administered through a nasal cannula comprising: a first lumen, a second lumen, and a third lumen: the first lumen being a first therapeutic gas lumen which delivers a gas comprising nitric oxide to the patient, the second lumen being a triggering lumen, and the third lumen being a second therapeutic gas lumen which delivers a gas comprising oxygen to the patient; and a cannula nosepiece allowing separate flow paths to the patient for each of (i) the first therapeutic gas lumen, (ii) the triggering lumen, and (iii) the second therapeutic gas lumen; and wherein the cannula nosepiece comprises a nitric oxide flow path having an inner diameter that is smaller than an inner diameter of the first therapeutic gas lumen. 14. The method of claim 13 , wherein the nasal cannula one or more of (i) reduces dilution of one or more of the first and second therapeutic gases delivered to the patient and (ii) is configured to be placed in fluid communication with at least one system to deliver one or more of the first and second therapeutic gases to the patient. 15. The method of claim 13 , wherein the nitric oxide flow path of the cannula nosepiece has a volume that is less than 10% of the volume of the pulse of the gas comprising nitric oxide. 16. The method of claim 13 , wherein the nasal cannula comprises one or more of (i) a wall material having a low oxygen diffusion coefficient and (ii) at least one valve in fluid communication with the first therapeutic gas lumen. 17. The method of claim 13 , wherein the nasal cannula is further comprising a fourth lumen: the fourth lumen being another first therapeutic gas lumen for delivering nitric oxide gas to the patient; and wherein the first lumen delivers nitric oxide gas to one nostril of the patient and the fourth lumen delivers nitric oxide gas to another nostril of the patient. 18. A method of administering nitric oxide for treating pulmonary hypertension, the method comprising: administering a pulse of a gas comprising nitric oxide to a patient, wherein the pulse is administered through a nasal cannula comprising: a first lumen and a second lumen: the first lumen being a combined first therapeutic gas and triggering lume

Assignees

Inventors

Classifications

  • Pressure sampling ports · CPC title

  • Methods of manufacture, assembly or production · CPC title

  • Non-controlled one-way valves, e.g. exhalation, check, pop-off non-rebreathing valves · CPC title

  • Nitric oxide [NO] · CPC title

  • Flow characteristics · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9795756B2 cover?
Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide. The nasal cannulas may reduce the total volume and potential for retrograde flow during nitric oxide therapy through the design of the specific dimensions of the flow path and/or having check valves in the nitric oxide delivery line and/or having a fla…
Who is the assignee on this patent?
Mallinckrodt Hospital Products Ip Ltd
What technology area does this patent fall under?
Primary CPC classification A61M16/0677. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).